Done ADHD Telehealth: Which Patient Profiles Should Avoid It

What Done Actually Offers and Why That Matters

Done connects adults in the United States to licensed clinicians who can evaluate, diagnose, and prescribe Schedule II stimulants for ADHD entirely online. The platform charges a flat monthly membership fee, bypassing insurance networks. That model works well for some patients. For others, it creates real clinical gaps.

The Schedule II Context

Stimulants prescribed for ADHD, including mixed amphetamine salts (Adderall) and methylphenidate (Ritalin, Concerta), are Schedule II controlled substances under the Controlled Substances Act. The DEA classifies Schedule II drugs as having "high potential for abuse which may lead to severe psychological or physical dependence." [1] That classification generates federal prescribing rules that no telehealth platform can waive.

During COVID-19, the DEA issued temporary exceptions that let telehealth providers prescribe Schedule II stimulants without an in-person visit. Those exceptions were extended through 2025, but the DEA's proposed special-registration rule, published in the Federal Register in 2023, would permanently restrict same-day Schedule II prescribing via telemedicine for patients who have never been seen in person. [2] Patients who start on Done now may face mid-treatment disruption if that rule is finalized.

How Done's Clinical Model Compares to AACE and AAP Standards

The American Academy of Pediatrics 2019 ADHD guideline recommends behavioral therapy as the first-line treatment for children under 6, and combined therapy plus stimulants for older children and adolescents. [3] Done does not treat minors. For adults, the guideline infrastructure is less rigid, but best practice still involves a structured diagnostic interview, collateral history where possible, and cardiovascular screening before initiating stimulants. A platform operating entirely asynchronously or through brief video visits may not consistently meet that bar.

Patient Profiles That Face the Highest Risk With Done

The patients below are not categorically barred from any telehealth platform. They are the profiles for whom Done's model, specifically, introduces the greatest clinical and safety risk.

1. Patients With Cardiovascular Disease or Uncontrolled Hypertension

The FDA labeling for amphetamine salts carries a black-box warning: "Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems." The same warning extends to adults, noting risks of "sudden death, stroke, and myocardial infarction." [4]

Blood-pressure elevation is dose-dependent. A 2012 meta-analysis published in JAMA (Vetter et al.) found that stimulant use in patients with pre-existing hypertension raised systolic blood pressure by a mean of 5.1 mmHg, a clinically meaningful increase in patients already near Stage 2 thresholds. [5] Done's intake process does not include auscultation, EKG review, or in-person cardiac exam. Patients with:

• known coronary artery disease
• uncontrolled hypertension (systolic >160 mmHg)
• congenital heart defects
• serious arrhythmias

Should not initiate stimulant therapy through any platform that cannot verify cardiac status before the first prescription. Done cannot do that.

2. Patients With Active or Recent Substance-Use Disorder

Schedule II stimulants carry significant abuse potential. The FDA-approved labeling for mixed amphetamine salts states plainly: "Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred." [4]

SAMHSA's 2022 National Survey on Drug Use and Health found that 3.7 million Americans aged 12 and older misused prescription stimulants in the past year. [6] Telehealth platforms that cannot access state prescription drug monitoring program (PDMP) data in real time, or that rely solely on patient self-report, create a pathway for diversion.

Done's prescribers are legally required to check PDMP records in most states before issuing a Schedule II prescription. Whether that check is consistently performed and documented across thousands of asynchronous encounters is not independently verifiable. Patients with active opioid use disorder, alcohol use disorder, or a recent history of stimulant misuse should pursue in-person addiction psychiatry evaluation before any stimulant prescription.

3. Patients With Bipolar Disorder, Schizophrenia, or Psychotic Features

ADHD and bipolar disorder co-occur at rates estimated at 20 to 30 percent in adult psychiatric populations. [7] Stimulants can precipitate manic episodes in patients with undiagnosed or undertreated bipolar disorder. The FDA labeling for amphetamine products notes that "prior to treatment, screen patients for bipolar disorder," because stimulants may induce "mixed/manic episodes." [4]

A brief video intake does not reliably distinguish ADHD inattentiveness from the distractibility seen during a hypomanic episode. Patients with:

• a prior manic or hypomanic episode
• psychosis or schizophrenia spectrum disorder
• active suicidal ideation

Need a more thorough psychiatric evaluation than Done's model provides before stimulant initiation.

4. Patients With Uncontrolled Anxiety or Panic Disorder

Stimulants worsen anxiety in a meaningful proportion of patients. A randomized controlled trial published in the American Journal of Psychiatry (Adler et al., 2009, N=280) found that approximately 27 percent of adult ADHD patients discontinued mixed amphetamine salts due to adverse effects, with anxiety and insomnia among the leading causes. [8]

Patients whose primary presenting problem is anxiety, or who have a diagnosis of panic disorder or generalized anxiety disorder that is not currently well-controlled on medication, may have their anxiety substantially worsened by stimulant titration. Done's intake does not include validated anxiety instruments administered by a psychiatrist. The GAD-7 is a self-report screen. It is not a psychiatric evaluation.

5. Patients in States With Active Telemedicine Prescribing Restrictions

Not all U.S. States have adopted the same telemedicine prescribing frameworks. Several states impose additional barriers to telehealth-only Schedule II prescribing, including requirements for an in-person visit before the first controlled-substance prescription, mandatory prescription drug monitoring, and physical-address verification for the prescribing clinician. [2]

Patients in these states may receive an initial evaluation through Done, pay the membership fee, and then discover that their state pharmacy board will not honor the prescription. Checking your state medical board's current telemedicine policy before enrolling is not optional.

Is Done Legit? What the Evidence Shows

"Is Done legit?" is one of the most-searched questions about this platform. The answer requires separating legal operation from clinical quality.

Regulatory and Accreditation Status

Done operates as a licensed telehealth platform. Its prescribers hold state medical licenses, and the platform has operated under the DEA's COVID-era telemedicine exemption. That is not the same as being accredited or independently validated for clinical quality.

As of 2024, Done is not accredited by the Better Business Bureau and carries a mixed consumer rating with complaints centering on billing disputes, abrupt prescription discontinuation, and difficulty reaching clinical staff. [9] LegitScript, which certifies online pharmacies and telehealth platforms for compliance with U.S. Pharmacy laws, had not granted Done certification as of the most recent public database check. [10]

The FTC and DOJ actions against other telehealth stimulant platforms in 2023 and 2024 (notably the Cerebral and Done Health federal investigations) raised specific concerns about whether intake processes adequately screened for contraindications before issuing stimulant prescriptions. Done Health (a related but distinct entity from the "Done" platform reviewed here) entered into compliance discussions with federal regulators. These actions signal that the entire cash-pay stimulant telehealth sector faces increasing scrutiny. [11]

Consumer Complaints: Patterns That Matter Clinically

Recurring complaint themes on the BBB website and third-party review platforms include:

• Prescriptions stopped abruptly without clinical explanation
• Patients unable to reach a prescriber for follow-up after adverse effects
• Billing charges continuing after cancellation
• No clear escalation pathway for urgent psychiatric concerns

Abrupt stimulant discontinuation is not medically dangerous in the way opioid withdrawal is, but it does cause rebound ADHD symptoms, fatigue, and mood disruption. [12] Patients who depend on continuity of prescribing, such as those whose job performance or safety depends on consistent symptom control, should factor that risk into their platform choice.

The HealthRX "Go / Pause / No-Go" Framework for Done

The table below summarizes candidate profiles based on this review.

| Profile | Recommendation | |---|---| | Adult with new ADHD diagnosis, no cardiac history, no SUD, stable mood | Go: Done may be a reasonable starting point | | Adult with well-controlled hypertension on stable antihypertensives | Pause: proceed only with PCP communication and baseline BP documented | | Adult with prior manic episode or active psychosis | No-Go: needs in-person psychiatry before stimulant initiation | | Adult with active or recent SUD | No-Go: in-person addiction psychiatry required | | Adult with serious cardiac history | No-Go: in-person cardiology clearance required | | Adult in a state with in-person-first Schedule II prescribing rules | No-Go: Done's model may not be legally valid in your state |

What FDA and DEA Rules Actually Require

Ryan Haight Act and Telemedicine Exceptions

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally prohibits prescribing controlled substances via the internet without at least one in-person medical evaluation. [1] The DEA granted COVID-19 public health emergency exceptions. Those exceptions allowed platforms like Done to operate. Post-PHE, the DEA proposed a special-registration pathway in 2023 that would allow telemedicine prescribing of Schedule II stimulants under specific conditions, including enhanced PDMP checks, clinical documentation requirements, and patient identity verification. [2]

The rule has not been finalized as of early 2025. That legal ambiguity is a real operational risk for patients mid-treatment.

FDA Stimulant Labeling Requirements

FDA-approved labeling for amphetamine-salt products (Adderall XR prescribing information, revised 2023) requires prescribers to assess patients for cardiovascular risk, bipolar disorder, and substance-use history before initiating treatment. [4] A telehealth intake questionnaire does not satisfy that requirement if it cannot elicit accurate history or perform a physical exam. Prescribers on platforms like Done bear individual liability for those assessments. Patients bear the clinical consequences.

Safer Alternatives for High-Risk Profiles

Patients who fall into the "No-Go" categories above are not without options.

For cardiovascular concerns, an in-person primary care visit with a 12-lead EKG and resting blood pressure measurement before stimulant initiation adds minimal cost and removes a major safety gap. The American Heart Association recommends cardiovascular evaluation before stimulant initiation in patients with known cardiac disease. [13]

For substance-use history, integrated addiction psychiatry programs, many now offering hybrid telemedicine plus in-person models, can conduct thorough assessments and manage ADHD within a monitored framework.

For bipolar comorbidity, a structured diagnostic interview using the MINI International Neuropsychiatric Interview (MINI) or the Structured Clinical Interview for DSM-5 (SCID-5), both requiring clinician administration, produces a more reliable differential than a self-report screen. [7]

Non-stimulant ADHD medications, including atomoxetine (Strattera), viloxazine ER (Qelbree), and guanfacine ER (Intuniv), are not Schedule II substances and can be prescribed through standard telemedicine without the same federal restrictions. [12] Patients with contraindications to stimulants should ask whether a non-stimulant trial is appropriate.

What Done Gets Right (and Where the Clinical Gap Remains)

Done lowers the access barrier to ADHD diagnosis and treatment for adults who lack insurance coverage or live in areas with few psychiatrists. Adult ADHD is underdiagnosed. The 2023 CDC data show that only about 4.4 percent of U.S. Adults carry an ADHD diagnosis despite prevalence estimates of 8 to 9 percent. [14] Cash-pay telehealth platforms have real value in closing that gap.

The clinical gap is not about convenience. Stimulants are among the most effective medications in psychiatry. A 2018 network meta-analysis published in The Lancet (Cortese et al., N=10,000+ across 133 trials) found that amphetamines produced the largest effect size for ADHD symptom reduction in adults (standardized mean difference 0.79, 95% CI 0.64 to 0.93) compared to placebo. [15] That efficacy is not in question.

The question is whether the prescribing process is safe enough for patients who bring significant comorbidities. For uncomplicated adult ADHD, Done may work. For the profiles listed in this article, the platform's structural limitations create risks that outweigh the convenience.